Modeling the Health and Economic Impact of Pharmacologic Therapies for MASLD in the United States
Summary Metabolic dysfunction-associated steatotic liver disease (MASLD), the most rapidly increasing and prevalent cause of chronic liver disease, is associated with substantial healthcare costs. As disease burden and costs mount, pharmacologic therapy which halts MASLD fibrosis progression is coming to fruition. Modeling the impact on disease progression of a hypothetical pharmacologic therapy which halts MASLD […]
English 
Spanish 
French 
Chinese 
Russian 
Arabic